The Chinese Domestic New Coronavirus Vaccine will Launch Soon with 100% Protection Rate

After Russia and India successively announced that they would skip the complete R&D process and launch vaccines, the safety of the vaccines of the two countries has been questioned by the Western world, and the actual effectiveness will not be accepted until after vaccination.

According to the information released by WHO, half of the vaccines currently entering Phase III clinical trials in the world come from China, which means that China's vaccine launch plan scheduled for the end of this year and early next year is very likely to be realized. However, the public has just begun to look forward to it, and China National Pharmaceutical Group has announced another news -- China’s domestic vaccine is expected to be available in December this year. Once the vaccine is put into production across the country, China’s epidemic control will begin again. In the final stage, the goal of people across the country taking off their masks and returning to normal life will surely be intended to achieve.

It is reported that the scope of global vaccine development includes inactivated vaccines and genetically recombinant vaccines and other programs. Up to now, seven vaccines from the United Kingdom, the United States, Germany, and China are entering the third clinical trial. Once they pass the trial , These vaccines will be officially put into production license. According to the person in charge of the Sinopharm Group, the principle of inactivated vaccines is to extract new coronavirus strains for cultivation, and use scientific methods to eliminate the infectivity and self-replication ability of live viruses, and only retain the parts that can stimulate the body to produce immunity. Under the same conditions, the development of inactivated vaccines is the fastest, but the cost is also quite high.

According to the patent approval issued by the Intellectual Property Department of China, a new coronavirus vaccine patent filed by an academician team of the Institute of Medicine of the Chinese Academy of Military Sciences in conjunction with Cansino Biology has been authorized. This patent application successfully proved that the vaccine should be soon Will be available.

Moreover, affected by related 'good news', the stocks of those country's biological companies have risen sharply lately, and clues in all aspects are telling us that the vaccine will become a savior and the day when the virus is completely removed is just around the corner.

According to media reports, in addition to explaining the principles of vaccine development to the public, the person in charge of the Sinopharm Group also personally vaccinated two doses of the vaccine. No adverse reactions have occurred. The person in charge pointed out that it may take a month and a half for vaccinators to produce virus antibodies after the first shot of the vaccine. This shot can provide a 97% protection rate for the human body, while the value of two shots can rise to 100%.

Since the cost of nucleic acid testing and patient hospitalization during the new coronavirus epidemic is quite expensive, the public is also very concerned about the price of the vaccine that will be on the market at the end of the year.

Judging from the estimation of Sinopharm, it was revealed that the cost of one shot of the vaccine is about several hundred Chinese Yuan (less than USD80), and the total price of two shots of the vaccine will not exceed 1000 Chinese Yuan (around USD150). Although this price is not cheap for local Chinese, it is within the acceptable range of most people. And only in large cities, students, office workers and other groups with frequent crowds must be vaccinated. Residents living in sparsely populated low-risk areas and rural areas can not be vaccinated. For a catastrophic epidemic, this vaccine cost can be regarded as a very small price.

Looking at the overall situation, although Russia has a faster production rate of vaccines, it may also consider exporting to China first, but their vaccine production cannot even keep up with domestic demand in the short term, and there are certain problems in safety. Now China has a stable vaccine must be able to eliminate the virus better and faster.